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Abstract: The rise and development of nanotechnology has permitted to create of a wide number of 10 
systems able to accomplish new and advantageous features to treat cancer. However in many 11 
cases, the lone application of those new nanotherapeutics has proven not to be enough to achieve 12 
acceptable therapeutic efficacies. Hence, to avoid these limitations, the scientific community has 13 
been embarked on the development of single formulations capable of combining functionalities. 14 
Among all possible components, silica –either solid or mesoporous–, has become of importance as 15 
connecting and coating material for those new-generation therapeutic nanodevices. In the present 16 
review there are visited the most recent examples of fully-inorganic silica-based functional 17 
composites, paying especial attention to those with potential biomedical applicability. 18 
Additionally, there will be given some highlights about their possible biosafety issues based on 19 
their chemical composition. 20 
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Drug Delivery 22 
 23 
1. Introduction 24 
The unstoppable advance of nanotechnology during the last decades has led to the 25 
development of a large number of nanomaterials with great therapeutic potential. Focusing on the 26 
treatment of cancer, the biomedical area with greatest penetration of nanometric based therapies, is 27 
possible to find a large number of materials suitable to treat an also large number of pathologies 28 
[1,2]. For example magnetic [3,4] and plasmonic materials [5–7] could be remotely excited with 29 
magnetic fields and light respectively to produce a thermal response capable of inducing cell 30 
apoptosis. Similarly, photodynamic chemical sensitizers [7] can generate Reactive Oxygen Species 31 
(ROS) inducing cell death throughout the oxidative stress pathway. Although these alternative 32 
therapies can improve the prognosis of the disease when employed as adjuvants, the truth is that 33 
chemotherapy remains as the reference treatment.  34 
Fortunately, delivery of chemotherapeutics have been also evolved, allowing the development 35 
of nanoencapsulated drug formulations able to improve the pharmacological profile of free drugs. In 36 
the clinic, liposomes [8,9] stand out, distantly followed by drug-protein hybrids and polymeric 37 
particles [1]. Nonetheless mesoporous silica (MS) based materials are slowly beginning to gain 38 
relevance because two unique properties: their well-established drug delivery properties [10,11] and 39 
their versatility to create high performing hybrid materials, which is the purpose of the present 40 
review. The classic features of Mesoporous Silica Nanoparticles (MSNs), related to their porous and 41 
robust structure, have given them notoriety in the academic field as drug delivery systems [12]. But 42 
in the last decade, the implementation of silica technology into other nanomaterials allowed the 43 
successful combination of several components in single nanometric entities. This, apart from an 44 
academic interest, has also aroused a certain clinical interest, since the additional nanosystems’ 45 
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functionality could be been successfully integrated with the well-known drug load capabilities of the 46 
MS.. Therefore, the multiple integration of features in single entities could be a pipe dream and its 47 
definitive weakness, since in the same way that raw nanomaterials have certain security issues and 48 
limitations, those are transferred to composite materials. In this review we will focus on the 49 
development of hybrid inorganic-silica materials with multiple features with applicability in 50 
nanomedicine and cancer treatment. Moreover, there will be discussed the additional features and 51 
known safety issues related to each functional silica-containing composites; however, as the MS will 52 
be common to all materials, we will begin with the biosafety aspects of silica. Apart from MS, there 53 
also have been reported other multifunctional devices based on different nanoplatforms [13–16]. 54 
Bulk silica is widely present in food additives and cosmetic products, which indicates low 55 
toxicity in the body; in general, silica is catalogued as “Generally Recognized as Safe” by the FDA 56 
(US Food and Drug administration, ID Code: 14808-60-7). Despite the demonstrated 57 
biocompatibility of bulk silica, when any chemical species is prepared as a nanomaterial, new risks, 58 
limitations and safety issues appear as a consequence of their tiny size. For example, the intimate 59 
interaction between particles and cells that allow nanomaterials to be assimilated by tumor cells, 60 
could generate unexpected side effects in healthy organs if they are accumulated or induce 61 
sensitization [17]. 62 
Despite these limitations, MSNs are considered too as safe materials for biomedical applications 63 
[18–20] as they suffer from slow hydrolysis in aqueous media [21–23] which may last up to weeks 64 
depending on pore conformation and functionalization. For raw MSNs matrix degradation is of 65 
capital phenomenon to properly determine the release kinetics; although in functional composites 66 
and modified silica this parameter is harder to control as more parameters apply and much less 67 
information is available. 68 
Apart from the degradability and the possibility to be excreted (Figure 1), there are other 69 
parameters and effects that should be accounted on MSNs in order to prepare them as nanomedical 70 
devices [23,24]. Size [25], shape [26–28], pore volume [29] and surface functionalization are also 71 
capital aspects. Regarding morphology, it is accepted that MSNs between 100 and 200 nm are the 72 
best performing particles; as those (1) avoid fast clearance [20] and acute toxicity [30,31] associated to 73 
small particles and (2) avoid aggregation on physiological fluids, blood capillaries and alveoli [32] 74 
associated to bigger particles. Moreover, rod-like particles seem to behave better than spherical ones 75 
thanks to the fact that multivalent interactions with membranes are easier [26,33]. 76 
 77 
Figure 1. (a): Major organs involved in the biodistribution of nanoparticles. (b and c): Schematic 78 
glomerular clearance possibilities depending on the biodegradability and size of nanoparticles. 79 
Adapted from reference [34] with permission. 80 
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Regardless of the morphology, the superficial modification of the MSNs plays a fundamental 81 
role in their efficacy and safety. First of all, it must be borne in mind that the use of the EPR effect 82 
alone, although could improve the behavior of the free drugs, is not often enough to give rise to 83 
personalized therapies and to improve the efficiency of available treatments. For this reason, there 84 
have been created a number of nanosystems able to increase the specificity towards certain cell 85 
populations. In this sense, a multitude of systems in which silica is coupled with recognition 86 
elements such as antibodies, aptamers and other bioactive fragments have been described [35–37]. 87 
On the other hand, it is also important to account that exogenous nanoparticles undergo a deposition 88 
of serum proteins as a result of the interaction with the immune system. This process called 89 
opsonization, leads to a strong surface modification -protein corona- [38,39] which produce the 90 
disruption of particles’ recognition abilities and finally to their elimination. Fortunately, 91 
opsonization could be mitigated by including highly hydrophilic polymers or fragments such as 92 
polyehtyleneglycol [40,41] or zwitterion structures able to create strong hydration layers onto the 93 
surface [42,43]. 94 
Besides surface modification, it is also important to consider that connections between 95 
components require from additional in-between layers. One of the most common substances for 96 
such purposes is dense silica, usually employed in thicknesses around several nanometers. The role 97 
of this intermediate layer usually goes beyond providing chemical inertness and magneto-optical 98 
transparency. It also permits to physically separate both components, avoiding physicochemical 99 
processes like dissolution or passivation of the internal core and the quenching of 100 
fluorescent-labelled composites. Moreover, it also permits the generation of aditional mesoporous 101 
layers without adding complexity to the system. It is also important to account that these dense silica 102 
layers have demonstrated additional features, some of them reviewed below, as increased 103 
photothermal stability of cores or the possibility to tune relaxitivity of contrast agents in Magnetic 104 
Resonance Imaging [44-46]. 105 
In view of all these aspects, to currently classify MSNs as suitable devices for biomedical 106 
applications, they must comply with series of morphology and surface modification requirements 107 
aimed at minimizing the immune response –stealthing– and enhancing tissue/cell recognition –108 
targeting–. As expected, all these features must be also complied if silica-containing inorganic 109 
composites are intended for biomedical applications.  110 
2. Inorganic-Mesoporous Silica nanocomposites with magnetic response. 111 
2.1. Magnetic materials in the clinic 112 
The use of magnetic nanomaterials is one of the most active research areas in biomedical 113 
research [4447], as proven by the large number of these nanosystems ongoing clinical trials [2]. 114 
Usually, those magnetic materials consist on crystalline iron oxides whose surface has been 115 
engineered to avoid agglomeration and accelerated dissolution [4548]. Among known nanometric 116 
magnetic materials Superparamagnetic Iron Oxide Nanoparticles (SPIONs) are by far the most 117 
developed systems [4649]. In this way SPIONs are magnetized in the presence of external magnetic 118 
fields, while they do not show such behavior in its absence. Moreover, SPIONs show a diverging 119 
behavior depending on the external magnetic field. Hence, if constant magnetic fields are applied 120 
(permanent magnet), magnetized SPIONs could be remotely guided towards the magnet; while if 121 
under alternating magnetic fields, SPIONs suffer from magnetization shifts. If this oscillation is 122 
powerful enough, the continuous reorientation of the magnetization will generate a magnetic 123 
resistance which would be thermally dissipated. This effect, when employed on living systems, lead 124 
to heat-induced apoptosis known as magnetic hyperthermia [4750]. Additionally, SPIONs have 125 
broad applicability as contrast agents for Magnetic Resonance Imaging (MRI) [4851,52,49] since they 126 
could be easily modified to tune their affinity to cells or tissues. 127 
Regarding the biosafety of clinically interesting SPIONs is important to remark that iron oxide 128 
crystals smaller than 20 nm, suffer from quick clearance but outstanding biocompatibility [5053] and 129 
require from surface coating to obtain higher circulation times and immune stealthing. Among all 130 
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coatings, dextran, starch, or PEG polymers are the most employed; being  the low molecular weight 131 
dextran the most recurrent on clinical trials [2,50]. 132 
2.2. Iron Oxide-Mesoporous Silica Nanocomposites (IOMSNs) as drug delivery agents. 133 
The coating of raw SPIONs with silica is of interest because it allows to increase time-stability 134 
by preventing its dissolution and undesired aggregation processes, among other important features. 135 
Among all SPION-Silica hybrid species, the mesoporous ones have special relevance as allow to 136 
develop Magnetic Drug Delivery Systems (MDDS). Nevertheless this coating also may induce use 137 
limitations, as a MS shell may produce thermal insulation of the magnetic core [5154]. This effect, 138 
although with little relevance in MRI and magnetic guidance, needs to be accounted if 139 
Magnetothermal-chemotheraphy (MTCT) is intended [5255]. Despite the improved in vivo stability 140 
provided by the silica coating of IOMSNs, this outer shell must be also chemically modified to avoid 141 
the interaction with adhesive proteins of the immune system [5356]. This could be achieved by any 142 
of the conventional coating procedures known for silica: polyethyleneglycol, [57,5854,55] small 143 
targeting elements, functional polymers, zwitterions, small-interferring RNAs (siRNAs) deposition 144 
and coating with membranes; although none of these materials have still reached clinical studies as 145 
far as we know (Figure 2). Among all surface coatings developed so far, PEG is by far the most 146 
recurrent component for SPIONs and IOMSNs [5659]. However, if such MDDS are not properly 147 
targeted, they would show a limited cell uptake and incremented off-target accumulation which 148 
may lead to severe problems of misplaced heating. To avoid this, many efforts have been devoted to 149 
the development of PEG-modified polymers able to efficiently target cells. 150 
 151 
Figure 2. Typical strategy employed for the preparation of drug-loaded, polymer-coated, targeted 152 
IOMSNs reviewed herein. 153 
Besides PEG-based polymers, there are many other interesting examples of polymer coated 154 
IOMSNs composites in the literature. For example, Zhang and coworkers employed a 155 
poly-dopamine pH-sensitive shell to retain Doxorubicin (DOX) within the mesopores [5760]. 156 
Additionally, this system was functionalized with a folate-modified PEG to provide targeting 157 
towards HeLa breast cancer cells. The efficacy of this coating was assessed using cell viability 158 
studies, which demonstrated high survival rates in vitro when the coating was present. The folate 159 
targeting employed permitted to reach high values of tumor accumulation without significant 160 
accumulation onto major organs. In another example by Hanagata there was designed a 161 
thermosensitive polymeric shell for IOMSNs [5861]. Herein, the chosen N-isopropylacrylamide 162 
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(NIPAM) containing polymer had the ability to change its conformation from globular to expanded 163 
when heated. With this system the authors could efficiently deliver DOX in combination with 164 
magnetic induced heating. This system proved to have an enhanced apoptotic effect on HeLa cells. 165 
Moreover, Guisasola et al. [5962] employed an equivalent device in vivo. On this work it could be 166 
seen that combination of hyperthermia and chemotherapy leaded to tumor growth reversion, 167 
demonstrating the potential of MTCT. 168 
Other common polymer employed on MDDS is polyethyleneimine. This is widely employed 169 
because of its cationic character that permits to bridge together negatively charged moieties like 170 
particles and nucleic acids. For example, Lee and coworkers developed a multilayered Zn-doped 171 
IOMSNs magnetic device able to successfully deliver DOX and the lethal-7a (let-7a) micro RNA 172 
(miRNA) able to disrupt Heat-Shock Protein expression. To do so the authors prepared negatively 173 
charged, phosphonate IOMSNs which were coated with PEI, (10 kDa) polymer. Then onto it was 174 
deposited the miRNA and a RGD modified PEI layer [6063]. The resulting RGD-targeted cationic 175 
assembly provided enhanced internalization on MDA-MB-231 breast cancer cells. This MDDS 176 
provided a satisfactory tumor volume reduction although magnetic hyperthermia was not 177 
employed. 178 
Although polymer coating of raw and hybrid MSNs enables outstanding retention of drugs 179 
within the mesopores, it is necessary to account that those polymers usually have associated severe 180 
drawbacks due to their limited degradability and/or intrinsic toxicity. For example PEI polymers 181 
larger than 25 kDa [6164] are known to highly destabilize cell membranes promoting apoptosis, 182 
unreacted NIPAM monomers are highly toxic [6265], while PEG polymers are generating a growing 183 
immunity [63,6466,67] due to their ubiquity in pharmaceuticals. For these reasons, many research 184 
groups are trying to avoid those issues by moving towards the use of more convenient biogenic 185 
elements to develop targeting and gating. For example, Popova et al. employed chitosan and alginate 186 
polymers to make a multilayer coating of sulfonate modified IOMSNs [6568]. This double coating is 187 
based on the electrostatic interaction of the cationic chitosan with both anionic IOMSNs and the 188 
alginate layer. This particular assembly permitted to load two different drugs mitoxantrone, within 189 
the mesopores, and prednisolone in between the chitosan-alginate layer. Other example was 190 
reported by Sinha et al. who deposited dextran onto boronic acid modified IOMSNs [6669]. This 191 
system proved to be sensitive to glucose, which was able to displace the dextran chains from the 192 
boronic acid. This system proved to successfully deliver Camptothecin on HeLa breast cancer cells 193 
thanks to the presence of folic acid as targeting agent. Unfortunately, the potential of this device was 194 
not fully tested as the combined apoptotic effect of MTCT was not addressed. Glycopolymers have 195 
been also employed for coating IOMSNs; for example, Lactobionic-2-aminoethyl methacrylate and 196 
3-(Methacryloxy)-propyltrimethoxysilane were co-polymerized onto IOMSNs for drug delivery 197 
[6770]. In this case, the pH-sensitive polymeric shell was able to retain DOX, unless a lysosomal 198 
escape occurred. Although the potential of MTCT was not addressed, the authors determined the 199 
fate of these MDDS in a murine model employing MRI detection. 200 
In order to enhance composites’ performance, other exploited approach is the modification of 201 
the surface with targeting elements. In an interesting contribution by Gao et al., folic acid was 202 
employed as coating for the silica layer [6871] to develop a targeted system able to exert MTCT. On 203 
this system, as there was not included a thermo-responsive nanogate, so the DOX release showed 204 
the same pattern in presence or absence of the alternating magnetic field. As expected, the 205 
application of a simultaneous MTCT showed a synergistic apoptotic effect in vitro on human MCF-7 206 
breast cancer cells. Similarly, a recent paper by Kariduraganavar and coworkers employed IOMSNs 207 
with transferrin on its surface to address U87 human glioblastoma cells [6972]. Moreover, the 208 
authors employed a Blood-Brain Barrier model to demonstrate that these nanosystems are able to 209 
cross this barrier. 210 
Apart from biogenic moieties, many functional modifications have been also included onto 211 
IOMSNs. For example Portilho et al. designed a theranostic system using a surface 99Tc-containing 212 
ligand for SPECT imaging with dacarbazine for the detection and treatment of melanoma [7073]. 213 
Other synthetic approach, aimed at improving the circulation time is the use of zwitterion elements 214 
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on the surface. Those molecules with perfectly balanced but separated charges are known to create a 215 
strong hydration layer that prevents protein adhesion [7174]. In a nice example by Sánchez-Salcedo 216 
et al. phosphonate capped IOMSNs were coated with a low-weight cross-linked PEI onto which was 217 
grafted a zwitterion phosphorylcholine fragment [7275]. Moreover, on this nanosystem the 218 
remainder free amino groups from PEI were balanced with a siRNA to achieve multimodal 219 
magnetically induced MTCT plus gene silencing. For the time being this system has only been 220 
partially tested in vitro with promising results on Ovcar8 ovarian cancer cell line. 221 
In addition to polymers and small molecules other promising coating for IOMSNs are lipid 222 
bilayers [7376], similarly as the so-called protocells. In a pioneering example by Mattingly et al. there 223 
was employed a cationic lipid shell to entrap DOX within IOMSNs [7477]; unfortunately, this 224 
magnetic protocell led to a relevant death rates on tested cells due to the cationic lipid bilayer 225 
employed. Nevertheless, this example set the basis for Sen and coworkers to design a phospholipid 226 
coated system to deliver DOX to MCF-7 and U87 cell lines [7578]. In this case the authors obtained an 227 
outstanding biocompatibility unless drugs or magnetic hyperthermia were applied. More recent 228 
examples deepened in the potential of this capping strategy, as elegantly demonstrated by Li and 229 
coworkers, who cloaked their nanocomposite with red blood cell membranes [7679] to obtain 230 
excellent biocompatibilities and circulation times (Figure 3).  231 
 232 
Figure 3. Multifunctional protocells arise from the coating of Mesoporous silica-based composites 233 
with lipid bilayers. 234 
Besides organic and biological coatings, other interesting systems with promising behavior 235 
have been also developed. For instance, Liu et al., coated Folate-targeted IOMSNs with a fully 236 
biocompatible CaCO3 as acid-cleavable gatekeeper for Daunorubicin delivery [7780]. This strategy, 237 
although profits form a simple and effective end-cap coating method based on the precipitation of 238 
CaCO3 from CaCl2 and Na2CO3, seems to affect the targeting capabilities of the complete system as 239 
suggested by the loss of preferential uptake. 240 
2.3. Magnetic Composites with applications in Nuclear Magnetic Imaging (MRI). 241 
The use of superparamagnetic materials in MRI is of great importance to achieve better contrast 242 
between tissues [4851]. In the case of transversal magnetization imaging (T2 weighted MRI, 243 
employed mainly for low-fat highly hydrated tissues) SPIONs are known to shorten spin−spin 244 
relaxation time of water and to provide better contrast in lean tissues such as liver, spleen and 245 
kidneys. On the other hand, longitudinal magnetization imaging (T1 weighted MRI, more useful to 246 
visualize tissues with high fat or low water contents) is improved when paramagnetic cations –Mn2+, 247 
Gd3+ and mainly Fe3+– are used as sensitizers. 248 
Unlike sensitizers exclusively designed for MRI, nanodevices containing metal and silica oxides 249 
are gaining interest as they can be employed for simultaneous diagnosis and therapy –theranosis– 250 
[78,7981,82]. However, the sensitivity provided by IOMSNs for T2-MRI is usually lower than those 251 
of SPIONs. This effect, caused by the shielding effect of silica, could be reversed if metal oxides are in 252 
the outermost layer of the composite Moreover, the sensitivity provided by IOMSNs for T2-MRI is 253 
usually higher than those obtained for SPIONs, as recurrently demonstrated on the literature [83,84]. 254 
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This effect could be also obtained by increasing the number of sensitizers throughout strategies that 255 
employ a greater number of metal oxides, which would be generally placed at the outermost layer of 256 
the composite. Those Mesoporous Silica-Metal Oxide Nanocomposites (MSMONs) show promising 257 
properties because of the higher metal loads achieved and the outstanding biocompatibility of 258 
components. Nonetheless, this approach has also limitations, as coating nanoparticles must be 259 
functionalized too to avoid all undesired aggregation processes, opsonization, off-target uptake 260 
and/or immune response. 261 
The coating of MSNs with SPIONs was first reported by Victor Lin’s group who designed a 262 
stimuli-responsive delivery system using silica nanorods [8085]. Although this responsive 263 
composite was intended as a proof of concept, the authors clearly outlined a future biomedical 264 
approach as they employed a redox-cleavable linker sensitive to biogenic compounds. More 265 
recently, Hyeon and coworkers developed PEG-coated MSMONs employing chemical ligation 266 
between amino capped MSNs and bromoalkyl-modified SPIONs [8186]. To do so, PEGylated the 267 
outer surface following a two-step methodology: (1) reacting the amino groups with a succinimidyl 268 
carboxylate PEG which was then (2) functionalized with previously PEGylated SPIONs. This model 269 
exemplifies the difficulty of preparing those MSMONs, which apart to need from two different 270 
stealthing agents, must be carefully synthetized to avoid massive aggregation between particles. 271 
With the previous design in mind and with the purpose of developing a synchronous T1 MRI 272 
contrast agent Zou and coworkers developed a MSMONs employing Ultra-small Manganese Oxide 273 
Nanoparticles to cap mesopores [8287]. Those caps could quickly dissolve under weakly acidic and 274 
release Mn+2 to enable T1 weighted imaging. Moreover, the authors employed DOX within the pores 275 
to have an additional therapeutic effect (Figure 4). Employing a similar strategy Huang et al. 276 
designed a system in which MSNs were doped with Fe+3 and loaded with DOX [8388]. This device 277 
proved to release ferric cations together with DOX when reached mild-acidic environments, 278 
accounting its use as a theranostic platform too. Moreover, although not reported, these 279 
DOX-loaded, metal-doped MSNs are supposed to be fully biodegradable as only Si, Mn and Fe 280 
oxides are employed on their synthesis (Figure 4). 281 
Regarding Gd, the most widely employed contrast agent for MRI, there have been also reported 282 
a broad number of systems. Like in previous examples, the strongly paramagnetic Gd+3 ions could be 283 
either located onto the surface of MSNs throughout known chelants, doped within the porous silica 284 
matrix, or even as a core-shell structure. The first approach, chelation throughout ligands, proved to 285 
be suitable for the generation of MSNs with contrast properties for MRI [89,90]. Along this line, it is 286 
important to remark the work by Davis and coworkers, who determined that surface location of 287 
Gd-chelates led to better contrast and sensitivity [91]. Unfortunately, this approach has a severe 288 
drawback, as surface modification is highly limited and complex due to the presence of Gd-chelates. 289 
For this reason new strategies have been developed for the incorporation of Gd into functional 290 
nanosystems. One of those possibilities is doping the silica matrix, which liberates the surface for 291 
further functionalization. However, a poor signal-to-noise ratio arises as a consequence of placing 292 
Gd in a mismatched crystallographic matrix. Hence, to overcome this issue two strategies that 293 
employ compact Gd-matrices has been reported. The first, in which the Gd occupies the core and the 294 
silica the shell, has the advantage of enabling multimodal detection throughout T1 weighted MRI 295 
and NIR-emitting persistent luminescence. Moreover, such approach allow to further modify the MS 296 
layer with all the developed targeting and stealthing technology, as elegantly demonstrated by Yu 297 
and Chen groups [92,93]. The other possibility for obtaining solid Gd-containing matrices is based 298 
on the construction of Gd-shells [94]; although this strategy does not profit from the advantages 299 
associated to mesoporous silica coatings. 300 
The previous examples use MSNs to, upon thermal treatment, dope the silica matrix. This 301 
strategy, although suitable for the release of paramagnetic cations, does not enhance the 302 
SPION-mediated T2 imaging. To solve this problem, Miao and coworkers devised a strategy in 303 
which MSNs were coated with core-shell SPIONs@MnO nanoparticles [8495]. This system could be 304 
disassembled when either (1) pH is below 5, (2) Glutathione (GSH) is overexpressed or (3) ROS are 305 
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above normal values. As expected, such system showed negligible effect on the viability unless 306 
Camptothecin was loaded, thus demonstrating an outstanding biocompatibility. 307 
 308 
 309 
Figure 4. Possible strategies for the preparation of Mesoporous silica-containing composites for MRI 310 
detection. (a) SPIONS contained in IOMSNs enable T1 weighted MRI while the outer mesoporous 311 
silica shell facilitates the development of hyperthermia-triggered systems. (b) Dopping the silica 312 
matrix with acidic cleavable contrast cations for T1 weighted MRI.  (c) Capping mesopores with 313 
dopped SPIONs for favoring acidic release of T1 (SPIONs) and T2 (Mn2+) contrast agents. 314 
Regarding the biosafety of those species, there should be accounted that capping 315 
nanoparticles must comply with all the premises made at the beginning of this revision. They 316 
must have an adequate surface functionalization to provide enough colloidal stability and to 317 
avoid the action of the immune system. Moreover, nanocaps must be either efficiently cleared 318 
or biodegraded; although in any case, use of small nanoparticles for capping purposes clearly 319 
aid in their final elimination. Regarding the cores, the use of ionic species (such as iron oxides 320 
reviewed herein or CuS and UCNs reviewed below) do not seem to be a problem regarding 321 
bioaccumulation as they degrade; although they may suffer from acute toxicity issues. But the 322 
use of non-degradable species (as Au) must be carefully addressed, as will be discussed along 323 
the following lines. 324 
2.4. Remote Homing of Magnetic Mesoporous Silica nanocomposites 325 
One of the most acclaimed applications of MDDS is the possibility of achieving magnetic 326 
guidance; although for magnetic silica composites is difficult to find successful examples. One of 327 
those is the model reported by Lee, which profited from a facilitated in vitro magnetic transfection to 328 
increase the apoptotic effect induced by hyperthermia plus DOX and let-7a miRNA co–delivery into 329 
glioblastoma multiforme cancer cells [6063].  330 
However, when magnetic guidance is intended in vivo, the round shaped composites do not 331 
seem to be the choice option. For these purposes, bifunctional nanobullets consisting of a Fe3O4 332 
magnetic head attached to a mesoporous silica tail seem to be a better option according to the results 333 
published by Dong and coworkers [85–8796–98]. On their first formulation, the authors employed 334 
Fe3O4 magnetic particles produced throughout high temperature hydrolysis with poly(acrylic acid) 335 
as surfactant. Then, onto those there were prepared MS rods upon a controlled addition of the silica 336 
precursor. The resulting MS tail was functionalized with amino groups onto which PEG was grafted, 337 
obtaining the desired Janus Iron Oxide Mesoporous Silica Nanobullets [8596]. This system was deeply 338 
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tested in vitro demonstrating a very nice biocompatibility together with evidences of energy 339 
dependent clathrin uptake. 340 
In vivo bioaccumulation of this system on HepG2 tumor-bearing mice demonstrated a preferred 341 
accumulation on the spleen. However, when magnetically targeted, the liver and the hepatic tumor 342 
were the tissues with highest accumulation, proving an effective magnetic guidance. Unluckily, 343 
despite the obtained tumor accumulation, the use of these nanobullets as DOX delivery agents did 344 
not improve the use of free DOX. To overcome this negative result, in a subsequent investigation the 345 
authors implemented the system by using a prodrug (Ganciclovir) loaded in the mesopores plus the 346 
herpes simplex virus thymidine kinase (prodrug activator) outside the pores. To retain the enzyme 347 
within the carrier the system was finally coated with a poly(L-lysine)-poly(ethylene glycol) layer 348 
grafted onto the carboxylate-modified nanobullets throughout amide coupling [8697]. Both in vivo 349 
and in vitro studies showed that combined guidance and MTCT permitted to significantly reduce the 350 
viability of cells and tumor sizes. More recently, these authors kept on studying the possibilities of 351 
this bullet-like MDDS, in this case to deliver curcumin to HepG2 cells [8798]. The result of combining 352 
these three effects: magnetic induced delivery, hyperthermia and curcumin delivery was an effective 353 
tumor reduction; which was not obtained when any of these three proapoptotic factors were absent. 354 
In addition to it, in these works the authors tackled too four different but important aspects of 355 
MDDS: (1) they compared the round-shaped (isotropic) core-shell disposition against the nanobullet 356 
(anisotropic) configuration, finding higher drug loading and faster release on the nanobullets; (2) the 357 
bullet-like materials demonstrated better magnetic guidance and hyperthermia due to their 358 
non-insulated magnetic head; (3) nanobullets provided an enhanced gene delivery when compared to 359 
the core-shell IOMSNs and finally (4) proved that the use of hyperthermia in combination with the 360 
gene suicide therapy led to a significant tumor growth control. 361 
In summary, Dong’s group have demonstrated the versatility of their nanobullets platform for 362 
multifunctional nanosystems, as they successfully accomplished: remote guidance, drug delivery, 363 
hyperthermia and MRI. Moreover, the use of stealth PEG-based coatings, permitted to reduce 364 
aggregation and immune system clearance thus favoring diffusion and increasing the therapeutic 365 
effect. As a drawback, the authors did not address yet the use of efficiently targeted nanobullets 366 
which might improve the efficacy of the magnetic-induced accumulation (Figure 5). 367 
 368 
Figure 5. Janus-nanobullets employed for magnetic-targeted drug delivery. 369 
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2.5. Magnetic Based Nano- and Biosensors 370 
Magnetic materials have in nanosensors another important field of development. One of the 371 
most promising approaches, although restricted to in vitro assays, is Magnetic Relaxation Switching 372 
[8899]. This strategy profits from the increase of T2 transversal relaxation time suffered by SPIONs 373 
when aggregated; which if caused by an analyte, would enable to develop MRI [89100] or 374 
relaxometry [90101] based-sensors. However, this approach is not suitable for most of systems 375 
described herein as the MS layer do not permit such close contact aggregation. 376 
In addition to them, magnetic nanomaterials have been also described as lipophilic-sample 377 
enrichment systems; which are based on the interaction of hydrophobic-coated SPIONs with 378 
lipophilic substances. Please refer to the following reviews to deepen in the uses of hydrophobic (C8 379 
to C18 chains, Carbon nanotubes, Graphene, Surfactants, Polymers, etc.) modified IOMSNs 380 
[91,92102,103]. From a safety point of view, although those nanosystems are able to adsorb 381 
substantial amounts of highly lipophilic proteins and analytes; the nature of those surface 382 
modifications make these systems extremely incompatible with living organisms and restrict their 383 
use only for in vitro purposes.  384 
2.6. Magnetic biostimulators 385 
Another important aspect of magnetic therapy is the remote induction of latent behaviors in 386 
treated cells. Among them, the most exploited is hyperthermia, an apoptosis inductor; however new 387 
interesting possibilities for other bone diseases have been also reported [93104]. Along this line, 388 
Deng and coworkers, employed IOMSNs arrays to suppress osteoclast differentiation [94105]. This 389 
effect opened the way to develop novel therapies for osteoporosis; mainly when in combination with 390 
the antiresorptive effect of zoledronic acid. For preparing such arrays the authors prepared silica 391 
coated SPIONs. Then, those were aligned to an external magnetic field, maintaining the alignment 392 
thanks to a magnetic dipolar interaction, then it was possible to coat the array with an additional 393 
mesoporous layer. The resulting linear, stable mesostructures could be prepared in up to 15 μm. The 394 
considerable length showed by this particular composite material permitted to remotely induce 395 
shear forces which proved to inhibit osteoclasts differentiation in concentrations above of 62.5 396 
ng/mL. However, despite the significant advance could be the remote disruption of the resorptive 397 
pathway for osteoporosis, the biosafety of this material could be questioned; first the enormous 398 
(from 1 to 15 μm) length might induce severe embolisms by composites’ aggregation, mainly after 399 
considering that the outer silica layer is not treated with stealthing agents. But also, the delivery of 400 
those materials towards the target could be problematic due to their complicated delivery to the 401 
bone. Notwithstanding all their limitations, the evolution of those IOMSNs’ nanochains is of an 402 
extraordinary interest, as it described the first remotely-triggered example for treating osteoporosis. 403 
3. Inorganic-Mesoporous Silica nanocomposites responsive to light. 404 
3.1. Nanomaterials with thermochemical response: Photothermal and Photodynamic effects. 405 
It is well known that certain materials are able to interact with light producing physical effects 406 
different from refraction, absorption and dispersion. In some cases, the light stimulation may 407 
produce either a thermal or an electronic excitation, which could be of interest for biomedical 408 
applications. In this way, if the resulting effect is thermal, it will be considered as a photothermal 409 
effect (PTE) [95106], while if it is a light-driven chemical excitation, we would talk about 410 
Photodynamic Effect (PDE) [107,10896,97]. This second effect is originated when the electronic 411 
excitation is relaxed by an energy-transfer to surrounding molecules, leading to ROS  that may 412 
undergo oxidative stress in living systems. The third possibility considered herein is luminescence, 413 
which will be reviewed below. All those possibilities have proved their feasibility for biomedical 414 
applications thank to a number of highly interesting contributions; although in some cases their use 415 
is not exactly innocuous. 416 
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The Photothermal Effect can be achieved either with organic or inorganic materials. The organic 417 
ones include the use of carbon allotropes [98109] (graphene, nanotubes, etc.) and conjugated 418 
polymeric materials [99110]; whereas among the inorganics, the greatest exponent are those derived 419 
from Au [5,111100]. The common problem to all these materials is their enormous facility to 420 
accumulate in living organisms, as they are not easily biodegraded. This can lead to both long-term 421 
toxic effects and latent but unwanted, off-target photothermal effects. For this reason, it is of vital 422 
importance to use those photoactive species in sizes that allow an efficient excretion and in very 423 
small quantities. Fortunately, the development of composite materials with a MS coating, allow to 424 
tune the overall size avoiding their aggregation. Moreover, the use of silica for PTE is highly 425 
convenient because of its transparency in Near Infrared (NIR); although produces thermal insulation 426 
of the photothermal core and thus lower responses. Besides therapeutic PTE, NIR excitation could be 427 
also employed for on-demand drug delivery purposes, for more information on this topic, please 428 
refer to reference [101112].  429 
The PDE occurs when the sensitizer is able to gather photons and transfer them to other reactive 430 
chemical species. Photosensitizers (PS) could be either of organic and organometallic nature: 431 
phenothiazinium cations, porphyrins, and phthalocyanines [102,103113,114], but also of inorganic 432 
nature. Among those, there have been reported examples of particles with PDE employing Fe3O4 433 
[104115], Ti2O [105116] and ZnO [106,107117,118] nanoparticles. Moreover, PDE is also common for 434 
Au and CuS nanoparticles, as a side relaxation pathway complementary to PTE. The use of PDE 435 
with Fe, Ti and Zn oxides is based on UV irradiation and has severe limitations for living systems. 436 
Fortunately, as will be discussed below, the use of UV radiation can be avoided by using composite 437 
materials containing upconversion particles, which are able gather photons from low energy 438 
radiation and convert them onto UV radiation able to excite photosensitizers and thus create the 439 
desired ROS. The main advantage of this strategy is the use of a harmless light source and the 440 
extremely localized generation of UV light, which only occurs where upconversion nanoparticles are 441 
present. Those two aspects enhance the biosafety of composites for PDE, although only if the PS is 442 
eliminable. For more information about PDE, please check the outstanding review authored by 443 
Lucky, Soo and Zhang [97108]. 444 
Besides their potential, non-degradable photosensitizers have severe side effects such as latent 445 
sensitivity, off-target accumulation and chronic toxicity. For this reason, the scientific community 446 
has been interested on the development of safer alternatives. Relevant examples for PTE induction 447 
could be achieved with degradable CuS [108,109119,120] and Fe3O4 [110121,122,111] crystals, which 448 
due to its ionic nature could be fully biodegraded. Unfortunately, up to our knowledge, there are no 449 
low risk photosensitizer alternatives for PDE. Their side-toxicity or latent reactivity must be always 450 
accounted in biomedical applications. An in-depth discussion of the advances that provide the 451 
combination of photodynamic or photothermal therapies together with anticancer drugs could be 452 
found in a previous review by us. Interested readers, please check reference [5255] for details.  453 
3.2. Inorganic Mesoporous Silica Nanocomposites for Photothermal Therapy. 454 
As previously introduced the most typical materials for PTE are Au species, and among them 455 
Gold Nanorods (GNRs). Nevertheless, they show two important limitations: the impossibility to be 456 
degraded and the presence of remainder surface surfactant CTAB hauled from its synthesis. 457 
Fortunately, the toxic cationic surfactant issue could be mitigated by coating the GNRs with a MS 458 
matrix. The resulting Mesoporous Silica Coated Gold Nanorods (MSGNRs) provide a stable coating 459 
that prevents aggregation and morphology shifts while preserves its plasmonic properties and 460 
thermal response (Figure 6). In a pioneering example Wu, Chen and coworkers were the first to 461 
deliver DOX with MSGNRs, [112123] proving that the simultaneous photothermal-chemotherapy 462 
(PTCT) provided an enhanced apoptotic effect. Inspired by the potential of PTCT, many other 463 
examples were reported in the following years profiting from the facile surface functionalization of 464 
the MS outer layer. Those modifications could be aimed at modifying the release profile of loaded 465 
drugs or to turn the systems into actively targeted devices. 466 
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  12 of 32 
 
Regarding the drug release modification, there could be found many examples in the literature. 467 
For example, the system designed by Lin, Qu and coworkers employed a pH-sensitive imine bonds 468 
to connect DOX and MS, obtaining a pH-driven release [113124]. On the other hand, there have been 469 
also reported targeted systems. In one of the first examples Liu et al. reported the surface 470 
modification of MSGNRs with a PEG polymer modified with a targeting tLip-1 peptide selective to 471 
the Neurophilin, a protein present in many cancer cell lines [114125]. 472 
Capped systems have been also object of study, although in this case the interest is shifted to 473 
thermally responsive systems more than for PTCT. In one of the previous examples Duget and 474 
coworkers have coated folate-targeted MSGNRs with a low-temperature (39ºC) melting 475 
biocompatible component [115126]. The 1-tetradecanol employed permitted to effectively coat the 476 
outer MS layer, thus allowing the retention of small molecules within the mesopores. However, 477 
when the system was exposed to NIR light and heated, the gatekeeper melted, and the drug could be 478 
released. In this case the authors did not pay attention to possible sensitivities to the 1-tetradecanol 479 
release, which may have disrupted the normal function of membranes and enhanced the overall 480 
apoptotic effect. On this same topic, our group developed a reversible nanosystem in which pore 481 
gating is accomplished by a NIPAM-based thermo-sensitive polymer [116127]. In order to get the 482 
appropriate functionalization and an adequate transition temperature a hydroxyl-containing 483 
monomer was included. Onto it there could be anchored and a bifunctional PEG that allowed to 484 
incorporate the melanoma-targeting NAPamide peptide. The system, evaluated in vitro, proved to 485 
be selectively accumulated into melanoma cells, producing the expected increase of cell death when 486 
combined PTCT was exerted. 487 
Apart from AuNRs, there are other Au species that show plasmonic properties. Among them, 488 
nanostars and nanoshells are the most promising (Figure 6). As expected, there have been 489 
successfully prepared hybrid species with MS. For a review dealing with Au@MS hybrid species, 490 
please check reference [117128]. Although the use of Gold Nanostars (GNSts) in combination with 491 
MS is very recent, there have been reported several examples with comparable efficiency to those 492 
obtained for the MSGNRs. In the first reported example using GNSts-MS hybrids, Zhang et al. 493 
designed a Janus-Au-Silica composite which was employed to successfully deliver DOX to HepG2 494 
cancer cells [118129]. Moreover, the Janus disposition of Au and Silica permitted to functionalize 495 
both subunits differently: Au was capped with a stealth PEG polymer while the silica moiety was 496 
decorated with lactobionic acid to gain in stability, biocompatibility, blood circulation time, and 497 
targeting towards cells bearing asialoglycoprotein receptors. Oppositely to the following examples, 498 
which employ already shaped GNSts, in this example the nanostar was prepared after the partial 499 
coating of an AuNP with MS. More recent examples dealing with GNSts could be on the literature. 500 
For example Mart nez-M{ ez and coworkers developed an AuNSt MS system coated with paraffin 501 
for DOX delivery [119130]; while Raghavan et al., employed GNSts@MS for theranostic simultaneous 502 
PTE and photoacoustic detection [120131]. In this last contribution the authors showed interesting 503 
results when a MS coated the nanostar: (1) a red-shift in the plasmon wavelength and (2) an 504 
enhanced photoacoustic effect. 505 
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 506 
Figure 6. Au-Silica based composites for photothermal applications. Gold nanorods, nanostars and 507 
nanoshells are able to transform near infrared irradiation into thermal energy. The combination of 508 
such remote stimulus with drug delivery opens new possibilities for highly efficient therapeutic 509 
nanodevices. Unfortunately, the poor biodegradability of Au species makes their application poorly 510 
recommended for many treatments. 511 
In addition to the strategy that employs Au embedded in a MS matrix, it is possible to carry out 512 
the opposite strategy, where Au particles are on the surface of regular MSNs. In addition to the 513 
expected greater sensitivity to stimulation with NIR, this strategy may simplify the gating process as 514 
the own AuNPs can act as nanogates [121132]. This coating strategy was followed by Li et al. to 515 
develop themoresponsive nanodevices with multimodal imaging possibilities using GNSts [122133]; 516 
demonstrating their adequacy for multimodal, ultrasonic, tomographic, photoacoustic and 517 
photothermal induced imaging. However, despite the promising future for these Au species, their in 518 
vivo behavior should be extensively evaluated. 519 
In a parallel way, there are another family of Au-Silica hybrids that present a similar 520 
distribution of components: Gold Nanoshells (GNSs)[123134]. Those materials are prepared by 521 
coating a template with a thin Au layer, being silica an outstanding platform for it because of its NIR 522 
transparency. Like Nanostars, GNSs could be employed for generating PTE, but not for the 523 
controlled delivery of drugs as the template is sacrificed in a non-degradable coating. Like bare 524 
GNRs, nanoshells can be easily functionalized employing the known reactivity of Au; but contrary 525 
to smaller particles, GNSs must be carefully employed in intravenous formulations as their great 526 
size and highly difficult elimination will cause a severe accumulation and thus a long-lasting 527 
remainder effects. Nevertheless, those GNSs could be used on topic applications as elegantly 528 
demonstrated by Mitragotri [124135] (Figure 7) and Nie [125136], who employed those materials for 529 
treating acne and melanoma respectively. Moreover, a PEG-coated silica-gold nanoshells have 530 
entered clinical trials for thermal ablation of solid primary and/or metastatic lung tumors 531 
(ClinicalTrials.gov identifier: NCT01679470), giving more arguments for silica to be used on 532 
nanomedical devices. 533 
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 534 
Figure 7. Two-step application of AuNSs for the treatment of acne. In this case the topical 535 
administration of the AuNSs, reduces significantly the risks associated to the “big” Au species. 536 
In addition to Au species, there have been reported other degradable systems with plasmonic 537 
properties [126137]. Among them, CuS has arisen as the most recurrent component among inorganic 538 
materials [108,109119,120]. Like other PS, CuS has been successfully embedded into MS matrices to 539 
obtain functional photothermally active composites. On the first example reported Song et al. 540 
prepared Cu9S5@mSiO2-PEG hybrids to treat Hep3B cells with simultaneous PTCT [127138], 541 
demonstrating a comparable loading capacity than the analogs containing GNRs. Additionally, 542 
hemolysis rates were similar for those obtained with PEG coated MS; thus validating the use of those 543 
nanocomposites suitable for combination therapy. Deepening on the topic, Zhu and coworkers 544 
employed an equivalent composite to successfully treat HeLa cells with a similar outcome [128139]. 545 
Besides PTE, CuS@MS composites have been also successfully employed in the development of 546 
materials for infrared thermal imaging and thermally responsive gated nanodevices. Along this line 547 
Zhang et al. reported the construction of a thermally triggered drug delivery nanodevices employing 548 
CuS@MS bearing aptamer-based nanogates [129140]. The resulting system was able to address 549 
MCF-7 cells due to the targeting capabilities of the aptamer and promote drug release when 550 
irradiated. For more information about the possibilities offered by DNA to develop mesopores’ gates 551 
and targeting, please check reference [130141]. 552 
In addition to the use of MS as coating component, CuS nanoparticles could also act as 553 
gatekeepers [131142]. In this model the authors employed a S-S cleavable linker to connect MSNs 554 
and CuS nanoparticles, enabling GSH redox-mediated cleavage of the system in intracellular 555 
environments. The viability studies showed cooperative apoptotic effects when the release of DOX 556 
was combined with the oxidative stress generated by GSH depletion and the induction of PTE 557 
throughout NIR irradiation. 558 
In another interesting approach, Huang and coworkers prepared CuS crystals within the MSNs’ 559 
mesopores employing thermal decomposition of Cu thiolates [131143]. In a latter step the authors 560 
functionalized the outer MS layer with the Ir-2 PS, thus enabling dual photothermodynamic 561 
combination therapy. The system was activated when the typical radiations for each component (535 562 
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and 1064 nm) wavelengths were employed, permitting to destroy HeLa xenografts in mice in less 563 
than 7 days. 564 
Other blooming field for CuS-containing composites is radiomedicine [132,133144,145]. In a 565 
visionary example on the topic, Cai and coworkers employed CuS@MS to create a traceable 566 
multifunctional nanodevice with targeting abilities. To do so, they decorated the outer MS layer with 567 
a TRC105 human/murine chimeric IgG1 monoclonal antibody and a 64Cu-chelated DOTA ligand 568 
[134146]. The resulting system combined (1) a highly effective targeting with (2) enhanced detection 569 
provided by the radioisotope and (3) the possibility of exerting PTE. This model, evaluated in a 570 
murine model, demonstrated a complete tumor destruction when photoablation was exerted.  571 
In addition to the photothermal effect described for Au and CuS species, very recently iron 572 
oxide nanoparticles have been reported to have a similar behavior [121,122,147]. This is of interest 573 
because the dual mode of action permits to access either deep tissues employing magnetic activation 574 
and surface tissues with light stimulation together with the MRI contrast capabilities of Fe oxides. 575 
Unfortunately, despite the enormous potential of combining magnetic and light excitation with a 576 
single device, up to our knowledge no studies on PTT in core-shell IOMSNs have been conducted 577 
yet. 578 
In summary, in the light of the reported examples, it is clear that combined PTCT increases the 579 
effect of independent therapies. Nevertheless, those results must be accounted carefully as the PTE 580 
itself is able to completely destroy tissues if enough irradiation is applied. This effect, known as 581 
photoablation, is very useful to apply different degrees of tissue destruction depending on the 582 
disease. Although it may be useful for treating highly resistant or difficult-to-operate tumors, it will 583 
always occurs at the expense of destroying completely the tissues. However, despite the huge 584 
potential of these materials, up to date no Au-based nanoparticles are approved by the FDA, 585 
although barely modified Au nanorods and nanoshells claim to be in the pipeline 586 
[1,2,135148,149,136]. Under these circumstances, it is logic to assume that biosafety and 587 
biocompatibility of Au-MS hybrids will take several years to become an available information. 588 
Indeed, to advance in the use Au for PTE, there is necessary to solve a number of unanswered 589 
questions like the power and duration of irradiation for an optimal therapeutic effect in different 590 
organs and tissues. But also there must be information about the adequate thickness [137150] and 591 
morphology [138151] of the mesoporous matrix and its possible thermal insulating effect; but also 592 
about the toxicity [139152], degradation and excretion processes related to nanomaterials for PTE. 593 
3.3. Nanocomposites for Photodynamic Therapy. 594 
As outlined previously PDE is a therapeutic effect based on the generation of ROS. However, in 595 
order to fulfill their function, it is important that ROS can effectively diffuse into the cytosol before 596 
self-destruction; so therefore, their generation should occur at the outermost surface of the 597 
nanosystems. Hence, it is logic to assume that the classical core-shell architecture in which the PS 598 
occupies the central position is not the more convenient, as the ROS must get through the dense MS 599 
matrix. This circumstance made the researchers to be interested in in surface decorated systems, 600 
which are easy to prepare employing organic photosensitizers [97108]. In addition to the previous, 601 
many researchers have also identified the generation of ROS as a side relaxation process after PTE 602 
generation. This could be employed to design multiple apoptotic inducing systems with a single 603 
photon excitation. Interesting examples have been described with Au [140153], CuS and CoS 604 
[141154], although none in combination with MS. For an outstanding and recent review on the 605 
modification of MSNs with different PS for PDE, please check references [142155,156] (Figure 8). 606 
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 607 
Figure 8. Photodynamic effect in therapy the light stimulation of is able to generate highly reactive 608 
oxygen species induce cellular apoptosis throughout oxidative stress and depletion of reductive 609 
species such as glutathione. The use of such dyes must be carefully addressed if they show long 610 
residence times, as their remainder activity may induce acute light sensitivity and chronic toxicity. 611 
Adapted from reference [143156]. 612 
3.4. Nanomaterials with light response: Fluorescence and Upconversion. 613 
Fluorescence and Upconversion are two similar phenomena; both implicate the absorption of 614 
photons and their transformation into an emission of different wavelength. The difference between 615 
these two processes relies on the wavelength of the resulting emissions. So, while the fluorescence 616 
produces a lower energy radiation, the upconversion transforms low energy photons into a high 617 
energy radiation via a sequential excitation of the material throughout an anti-Stokes process. 618 
Obviously for accomplishing upconversion there are required to gather two or more photons. 619 
As the outcome wavelength are different for both process, the application fields are different 620 
too. Fluorescence is the most important technique for detection of nanoparticles; being of interest for 621 
the detection and quantification of cell uptake and particles’ trafficking, fate and excretion [144157]. 622 
While on the other hand, upconversion materials could be employed for either bright field detection 623 
(fluorescence) or photodynamic therapy if the resulting radiation is able to trigger an apoptotic 624 
process or to excite a PS [97108]. Herein, it is also important to remark that luminescence of UCNs is 625 
efficiently quenched by water, so the construction of composite materials must need from an 626 
intermediate dense silica layer to isolate the photoactive core. 627 
Regarding the composition of these light-conversion materials, Upconversion Nanoparticles 628 
(UCNs) are generally formed by fluorides of lanthanide trivalent elements (La3+, Gd3+, Y+3 and Yb3+) 629 
which have replaced some of the cations by dopant elements such as rare earth metals like Yb+3, Er+3, 630 
Tm+3, etc. [145–147158–160]. On the other hand, excluding non-degradable C-dots [161–163148–150], 631 
Quantum Dots (QDs) are mainly composed by nanocrystalline metal chalcogenides (Zn2+, Cd2+ or 632 
Pb2+ plus S2- or Se2-) among many other minor compositions [151,152164,165]. As could be figured 633 
out, the composition of these kind of materials may have a relevant impact on the biosafety of both 634 
UCNs [153166] and QDs [154,155167,168]; although this topic has been still very poorly covered. In 635 
any case it is logic to assume that their ionic nature, would favor an eventual full degradation 636 
throughout dissolution of crystals; which upon reaching a critical size, could be cleared out. 637 
However, their degradation occurs at the expense of releasing heavy metals [155–158168–171], 638 
selenides and fluorides [159172] into the organism. As a result, these nanocomposites must be very 639 
carefully applied as they are formed by poorly biocompatible and toxic elements which might 640 
expose the patient to a continuous dosage and undesired bioaccumulation. However, it is also 641 
important to note that the composite materials based on UCNs and QDs use very small crystals that 642 
could be quickly cleared upon degradation of the composites; although again, not much information 643 
is available on this topic. 644 
The use of MS for the development of light-responsive composite nanomaterials allow to 645 
incorporate a porous layer which could be easily functionalized with polymers or targeting 646 
compounds and loaded with additional therapeutic compounds. Moreover, for most of applications 647 
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this MS matrix is highly transparent, which ensures a proper response of the light sensitive 648 
component as long as the rest of components do not interfere with the incoming radiation. 649 
3.5. Quantum Dot nanocomposites for bright field detection.  650 
Fluorescence imaging is by far the most exploited tool for the detection, trafficking and 651 
bioaccumulation determination of nanoparticles in biomedical applications. Fluorophores could be 652 
either of organic nature such as fluorescein and its derivatives or inorganic, like quantum dots (QDs) 653 
and carbon dots [148161]. Along this line, organic fluorophores have been successfully employed to 654 
prepare Cornell dots, which are the first in-human clinical trial for a silica nanocomposite. Those 655 
silica nanoparticles, loaded with the Cy5 fluorophore are functionalized with a PEG coating, and a 656 
124I radiolabeled cRGDY targeting peptide (ClinicalTrials.gov identifier: NCT01266096), are able to 657 
accomplish integrin recognition and hence to detect melanoma and brain tumors [160173]. On the 658 
other side, QDs offer advantages over the organic molecules, as they do not suffer from quenching 659 
and show higher quantum efficiencies with narrow adsorption and emission bands. The 660 
biocompatibility and the biomedical uses of QDs are highly dependent on their composition, which 661 
besides containing heavy metals, also include poorly biocompatible solvents employed on their 662 
synthesis [150,152,154,156,161163,165,167,169,174]. This issue could be partially solved by coating 663 
QDs with a silica/MS layer able to displace the coordinated solvents while preserving [162175] the 664 
QD core [163–165176–178]. Unfortunately, the intrinsic toxicity associated to the forming elements 665 
and remainder solvents in their composition make them risky for in vivo biomedical applications. 666 
Nevertheless their outstanding luminescence make them ideal candidates for bioimaging and 667 
biosensors, as could be guessed by the overwhelming number of publications in these fields [166–668 
169179–182].  669 
3.6. Mesoporous Silica containing Upconversion Nanocomposites  670 
Contrary to QDs, upconversion nanoparticles absorb low-energy photons and turn them into a 671 
higher energy emission. This property, interesting for the development of nanoprobes and sensors 672 
[170183], is also of interest for the development of therapeutic agents if the emission is energetic 673 
enough to perform cellular damage [171,172184,185]. For achieving so, light upconversion is usually 674 
combined with photosensitizers. 675 
In the first example of this kind, Idris et al. built a nanocomposite in which an Yb/Er doped 676 
NaYF4 UCN was coated with a MS layer containing two PDE sensitizers: Zinc phthalocyanine 677 
(ZnPC), merocyanine 540 (MC540) [173186]. This system was able to convert the incident 980 NIR 678 
radiation (2.5 W/cm2, 40 min) into visible radiation (550 and 660 nm respectively) able to 679 
independently activate each photosensitizer. The system was evaluated against B16-F0 melanoma 680 
tumors in a murine model employing both naked or folate-PEG surface modifications. Under these 681 
circumstances the targeted systems achieved a higher tumor growth disruption although without 682 
tumor remission. More recently Wu, He and coworkers improved the targeting ability of this system 683 
employing a novel biomimetic camouflage strategy using stem-cell membranes [174187]. The 684 
resulting upconverting protocells showed good stability and biocompatibility together with a 685 
prolonged blood circulation time and the tumor-tropic properties of stem-cells. The triggering of the 686 
proapoptotic PDE with this nanodevice permitted to reduce significantly the progression of HeLa 687 
tumors in mice; but only when the UCN@MS were coated. This result showed the huge potential of 688 
membrane-coated nanosystems for cancer treatment. Additionally, this strategy could be also 689 
employed for enhancing long-time circulation and low immunogenic response, as elegantly 690 
reported by Xuan et al. [7679], who cloaked their nanoparticles with red-blood cell membranes with 691 
outstanding results.  692 
The previous examples profited from a double sensitizer photodynamic therapy to develop 693 
highly efficient cancer therapies; however, in those examples mesopores were not occupied with any 694 
therapeutic agent. To cover this gap, Bu, Shi and coworkers developed a system for treating tumors 695 
with a synergistic reductive therapy based on the use of UCNs, together with a PS and a prodrug 696 
[175188]. For doing so the authors assumed that upon PDE triggering (ROS generation) hypoxic 697 
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environments are created. Therefore, if a prodrug that is activated under hypoxic conditions is 698 
co-administered, the apoptotic effect would be increased. The reported system employed Yb/Er/Gd 699 
doped NaYF4 UCNs coated with silica as platform, silicon phthalocyanine dihydroxide as PS and 700 
tirapazamine as prodrug. The potential therapeutic effect of the whole system onto HeLa murine 701 
xenograft tumors provided promising tumor growth inhibition despite it was a non-targeted 702 
nanosystem, demonstrating again the potential of combination therapy (Figure 9). 703 
 704 
Figure 9. Upconversion-Silica based composites for photodynamic therapy. The internal core of 705 
those species is able to transform near infrared irradiation into high energetic UV-Vis radiation 706 
suitable for exciting most of photodynamic sensitizers, known to generate oxidative stress mediated 707 
apoptosis. 708 
Additionally, UCNs@MS have been also successfully employed for drug delivery. In another 709 
contribution by Bu and Shi, an UV-Vis triggered azobenzene based nanoimpeller was employed to 710 
increase the outflow of DOX from the mesopores. In this case the system was completed with the 711 
fusogenic TAT peptide as targeting element [176189]. The authors claimed that the UCN was able to 712 
convert the incident NIR light (2.4 W/cm2) into a radiation able to photoisomerize the azobenzene 713 
and hence to favor the drug release acting as pore nanoimpellers. The in vitro evaluation on HeLa 714 
cells of the resulting system provided a nice correlation between irradiation time (5, 10, 15 and 20 715 
minutes) and cell mortality. The authors associated the higher death rates to higher DOX releases. 716 
However, Dong and Zink addressed an in-depth study of the nanoimpeller-mediated release 717 
mechanism [177190] finding that such enhanced DOX release did not occur due to 718 
photoisomerization. According to their investigations, the driving mechanism was a thermal effect 719 
created upon heating the UCN cores with the incoming 980 nm light; pointing out a PTE able to 720 
increase drug outflow, as demonstrated in light-induced drug release with UCN@MS in the absence 721 
of such nanoimpellers. 722 
Other possible strategy to achieve PDE with UCN@MS composites is trapping the PS into the 723 
mesopores as demonstrated by Han et al [178191]. In their system the mesopores were loaded with 724 
Rose Bengal and capped with an adamantane–cyclodextrin nanogate. This approach although did 725 
not significantly improve the therapeutic potential of other reported systems, opened the door to 726 
massive delivery of PS, which could be of interest for defining tumor burdens in post-treatment 727 
surgeries.  728 
Apart from upconversion of NIR into UV/Vis radiation, an interesting example has been 729 
reported for the downconversion process; although in this case the use of highly ionizing radiation 730 
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O2 / H2O
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limits significantly the applicability. For so, Hirata’s group designed a Gd-Al garnet for X-Rays 731 
downconversion [179192]. The system was completed with the Rose Bengal photodynamic sensitizer 732 
able to transform the downconverted light into ROS. Regarding this nanosystem, it is noteworthy 733 
that the Gd-Al garnet enabled two unprecedented features for light-activated nanomaterials: (1) 734 
enabled MRI detection and (2) the downconversion of X-rays permitted an unprecedented in-depth 735 
tissue remote activation of nanosystems. 736 
4. Multicomponent nanocomposites containing mesoporous silica. 737 
As already mentioned, the advantages of silica in the construction of nanomedical devices goes 738 
beyond its mere use as porous matrices. As reviewed, it also allows the connection of functional 739 
entities easily and quickly. In the case at hand, the construction of multifunctional systems, there are 740 
many examples that use silica to integrate different types of particles and create nanosystems 741 
responsive to more than one remote stimuli. Among all published combinations, the most common 742 
is one that uses light and magnetic stimulation simultaneously. Among them, the most common 743 
combination is the one that combines magnetic and light stimuli. To this end, many research groups 744 
employed already developed core-shell systems for the preparation of complex composites. 745 
Following this strategy, Gao et al. reported the development of a multilayered, folate targeted, 746 
Fe3O4@MS@CuS nanocomposite  able to accomplish targeted PTCT and MRI [180193]; while Yao et 747 
al. reported the preparation of Fe3O4@MS@QDs device able to perform drug delivery and 748 
magneto-photothermal therapy with an outstanding detectability [181194]. 749 
Besides the combination of SPIONs and AuNPs for magneto/photothermal theraphy, this 750 
combination is also very useful for the preparation of multimodal detection systems, as the SPION 751 
enables MRI detection and Au does the same for X-rays computed tomography [182195]. With this 752 
purpose Yang et al. prepared a multimodal detectable nanosystem in which a Fe3O4@Au composite 753 
was embedded into a MS matrix [183196]. This system was further modified with three apoptotic 754 
inducers: a PS for PDE, DOX and a siRNA, which permitted to obtain a tumor growth reversal in a 755 
MCF-7/ADR cells. Another multipurpose assembly of AuNPs and SPIONs, reported by Sánchez et 756 
al., grew AuNPs onto IOMSNs. The resulting anisotropic Au-coated Janus-Fe3O4@MS composites 757 
[184197] were able to perform MRI and computed tomography imaging. But in addition to previous 758 
systems, the incorporation of a fluorescent Alexa Fluor 647 dye onto the exposed part of AuNPs, 759 
permitted to enable conventional bright field optical detection too. Apart from Au, IOMSNs have 760 
been also combined with different inorganic species. For example, Cui and coworkers employed a 761 
silica coated Fe3O4@ZnO composite to achieve microwave-triggered drug release. In this case, the 762 
ZnO interlayer can acted as ultrasound-to-temperature converter although with poor efficiency 763 
[185198]. 764 
In the same way, core-shell UCN@MS composites have been also subject of additional 765 
modifications seeking for more versatile nanodevices for theranosis. Two examples with UCN cores 766 
were reported by (1) Shi and coworkers, who designed a system that combined radio- and 767 
photothermal ablation by using ultrafine radioactive CuS nanoparticles deposited onto a UCN@SiO2 768 
platform [186199]; and (2) by Liu et al. who successfully coated UCN@MS with SPIONs for 769 
accomplishing bioimaging plus magnetically targeted DOX delivery [187200]. Both examples, 770 
permitted to obtain great tumor destruction rates on murine models, demonstrating once again the 771 
potential of combining different functionalities into a nanodevice. 772 
 As reviewed so far, the combination of functional components in single nanometric 773 
formulations permits to combine apoptotic effects and hence to achieve better therapeutic profiles in 774 
the treatment of cancer. Unfortunately, to use these systems, there must be considered a large 775 
number of biosafety limitations. Those are not only consequence of the increasing complexity and 776 
number of connecting components, but also may be consequences of unforeseen side-effects that 777 
may arise when  different functional components coexist in complex, living systems. 778 
5. Conclusions. 779 
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  20 of 32 
 
Although raw silica nanoparticles are not approved nor employed as a pharmaceutical 780 
formulations, the use of mesoporous silica is widespread in the preparation of functional 781 
nanodevices Despite raw mesoporous silica nanoparticles have been not approved as a nanomedical 782 
formulations, the use of silica is widespread in the preparation of functional nanodevices. This is due 783 
to its extraordinary physicochemical behavior, biocompatibility, degradability and porous 784 
morphology. For this reason, materials formulated with silica in their composition have entered for 785 
the first time in the clinical studies pipeline; although there is still a long way to go before its use 786 
generalizes.  787 
From the data presented herein, there could be concluded that silica is no longer a material to be 788 
discarded by the pharmaceutical companies. Indeed, it must be considered and properly studied as 789 
one more possible component for nanoformulations, since it provides a unique plasticity to 790 
manufacture multifunctional devices. Above all, this must be tackled with rigorous studies of acute 791 
and long-term toxicity, bioaccumulation and clearance of nanosized silica to set a basis for modelling 792 
future composites. From a technical point of view, it is important to note that silica is a material that 793 
presents high permeation to (electro)magnetic fields and transparency against ultraviolet and 794 
infrared radiation, which allow to maintain unaltered the properties of the functional components 795 
From a technical point of view, it is important to note that silica is a material that presents high 796 
permeation to (electro)magnetic fields and transparency against ultraviolet and infrared radiations, 797 
which is of interest for obtaining adequate remote activation of functional components. In short, in 798 
light of the published results, our opinion is that the use of silica in composite materials favors its 799 
translation into clinical phases, since unlike other components, the use of silica does not require a 800 
large number of connectors, complex synthesis processes or poorly stable components. 801 
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